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Background. Dialysis patients have much higher mortality
rates than the general population. Anemia is a common compli-
cation of uremia and a major contributor to morbidity and
mortality in dialysis patients. The benefits of anemia correction
using recombinant human erythropoietin (rHuEPO) are well
established. Optimum hemoglobin level for dialysis patients
remain controversial. We have investigated the association of
enrollment hemoglobin with long-term survival in hemodialysis
(HD) and peritoneal dialysis (PD) patients.
Methods. We enrolled 529 HD and 326 PD patients from
1987 and followed them to April 2003. Demographics, enroll-
ment, and clinical and laboratory data were recorded. The
Kaplan-Meier method was used to compute observed survival,
and the multivariate Cox regression analysis was used to iden-
tify the independent predictors of mortality risk.
Results. Mean ages of HD and PD patients were 60  16
(SD) and 54 16 (SD) years, respectively. Forty-seven percent
of HD patients and 41% of PD patients were diabetic. Mean
enrollment hemoglobin levels of HD and PD patients were
9.44  1.9 and 9.61  1.77 g/dL respectively. Cumulative 15
year observed survivals of HD (P  0.05) and PD (P  0.032)
patients with hemoglobin levels greater or equal to 12 g/dL
were higher than those with hemoglobin levels less than 12
g/dL. Hemoglobin12 g/dL was a better predictor of mortality
in nondiabetics than diabetics, particularly in HD patients.
Both in HD and PD diabetic patients, hemoglobin was not a
significant predictor of mortality. By Cox regression analysis,
after adjusting for age, race, gender, and months on dialysis
at enrollment, the relative risk of mortality of patients with
hemoglobin12 g/dL was 2.13-fold (P 0.008) higher for HD
and 1.85-fold (P  0.06) higher for PD compared to those
with hemoglobin 12 g/dL (P  0.035). A logistic regression
analysis revealed a strong inverse relationship between the
hemoglobin level and the odds risk of death in HD (OR 
0.83, P  0.008) and in PD (OR  0.85, P  0.02) patients.
Conclusion. Enrollment hemoglobin is a predictor of long-
term survival in HD and PD patients. Patients with hemoglobin
levels that are higher than current treatment recommendations
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(12 g/dL) may benefit from long-term survival. Survival of
dialysis patients may be improved by better management of
malnutrition and anemia.
Anemia is a common complication of uremia [1]. The
impact of anemia on morbidity and mortality in dialysis
patients has received much attention [2]. Association be-
tween anemia and mortality risk may be mediated through
cardiovascular disease, malnutrition, and inflammation.
Correction of anemia raising the hemoglobin level using
recombinant human erythropoietin (rHuEPO) leads to
partial of correction left ventricular hypertrophy (LVH)
and other cardiovascular complications in dialysis pa-
tients [3]. However, even 15 years after rHuEPO therapy
became available, the target hemoglobin level to be
achieved for optimum improvement of well-being of di-
alysis patients remains controversial. While large multi-
center studies in the last 5 years have demonstrated clini-
cal benefits of increasing the hemoglobin, this single-
center study reports for the first time 15 years of data
describing the longitudinally predictive power of hemo-
globin for patients’ survival.
Malnutrition is highly prevalent in dialysis patients
and a major contributor of morbidity and mortality in
these patients [4]. Over the past decade, various nutri-
tional parameters have emerged as powerful predictors
of mortality in dialysis patients [5–8]. Among the newer
markers of nutrition, serum prealbumin has received
much attention. Because of its short half-life and small
pool size, serum prealbumin is a highly sensitive marker
of nutrition and survival in dialysis patients [9–12].
In the present study, we evaluated the association of
enrollment hemoglobin with long-term survival in hemo-
dialysis (HD) and peritoneal dialysis (PD) patients and
the inter-relationship between prealbumin and anemia
and their impact on mortality.
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METHODS
Patients
Five hundred twenty-nine HD and 326 PD patients
undergoing dialytic therapy at the Avram Center for
Kidney Diseases at Long Island College Hospital were
enrolled in the study in 1987. All patients were followed
through April 2003. Patients were censored on trans-
plantation, change of modality, and transfer to another
center. On enrollment, demographic and clinical data
collected included age, race, gender, diabetic status, eti-
ology of end-stage renal disease (ESRD), total months
on dialysis at enrollment, and seropositivity to human
immunodeficiency virus (HIV) (if known).
Laboratory analysis
Nonfasting blood samples were collected at routine
monthly visit and the multiphasic biochemistry screen
including albumin, creatinine, total cholesterol, and pre-
albumin were performed. Prealbumin was measured by
immunoturbidimetric method (Spectra East, Rockleigh,
NJ, USA).
Statistical analysis
Continuous variables were reported as mean  SD.
For selected comparisons between 2 group means, para-
metric (t test) or non-parametric (Mann-Whitney test)
wherever applicable were used. Correlations were re-
ported as either the Pearson correlation coefficient or
the Spearman rank correlation coefficient. Patient sur-
vival was analyzed, with death considered as final event.
Transfer to another center, or a switch to other modality
was regarded as censored information. Observed sur-
vival of patients was computed by Kaplan-Meier method
[13]. Log-rank test was used to compare survival curves.
Multivariate Cox regression analysis was used to deter-
mine independent predictors of survival. Logistic regres-
sion analysis was used to investigate the association
between risk of death and explanatory variables. Calcu-
lations were performed using SPSS for Windows 10.0.1
(SPSS, Inc., Chicago, IL, USA).
Dialysis prescription
Hemodialysis patients were treated with bicarbonate-
based dialysate and volumetric ultrafiltration control.
Cellulose-based membranes (predominantly cellulose
acetate and cellulose triacetate) were used prior to 1998
for more than 95% of all treatments. Thereafter, all
patients were switched to polysulfone membranes. Ini-
tially, the HD prescription was guided by the goal of
achieving a urea reduction ratio of 60% on the first
treatment of the week (i.e., 68 hours after the preceding
dialysis). This was later increased to 65%. Prior to
1992, most patients treated with continuous ambulatory
peritoneal dialysis (CAPD) received 4 2-liter Dianeal
solution exchanges per day. After 1992, PD prescription
was guided to achieve a weekly target Kt/V of 1.7, which
Table 1. Demographics of HD and PD patients
HD PD
Age at enrollment years (meanSD) 6016 5416
Gender %
Female 55 53
Race %
White 23 22
African American 60 59
Hispanic 17 19
Diabetes % 47 41
HIV-positive % 1.4 13
Months on dialysis at enrollment
(meanSD) 19.535 414
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; HIV, human
immunodeficiency virus.
was later increased to 2.1. Dextrose concentration in the
dialysate varied with the need for ultrafiltration.
RESULTS
Hemodialysis
Demographics, patient characteristics, and laboratory
data. The demographic and clinical characteristics of the
HD and PD patients are shown in Table 1. In HD pa-
tients, the causes of ESRD were as follows: 40% diabe-
tes; 31% hypertension; 11% glomerulonephritis; 4% po-
lycystic kidney disease; 2% obstruction; 1% HIV; and
11% other/unknown. At enrollment, the mean hemoglo-
bin and serum prealbumin levels were 9.44  1.9 g/dL
and 26.4 6.6 mg/dL, respectively. In addition, the mean
enrollment albumin was 3.66  0.51 g/dL, mean serum
creatinine was 10.9  4.7 mg/dL, and mean total choles-
terol was 180  53 mg/dL. The mean and maximum
follow-up times were 3.99 and 16.04 years, respectively.
Survival analysis by hemoglobin. During this study
period, 289 of the 529 HD patients (54.6%) died. Patients
were stratified by hemoglobin level 12 g/dL and 12
g/dL. The cumulative observed survival of HD patients
with enrollment hemoglobin 12 g/dL was better (P 
0.05) than that of patients with hemoglobin 12 g/dL
(Fig. 1). Subgroup analysis revealed that this survival
advantage was seen only for nondiabetic patients (Fig. 2)
(P 0.009) and not for diabetics (PNS). Interestingly,
enrollment hemoglobin was not predictive of survival
when stratified as greater than or less than 11g/dL (P 
0.29) or as greater than or less than 10 g/dL (P  0.24).
The independent predictors of patient survival strati-
fied by diabetic status were determined using a multivari-
ate Cox regression analysis, adjusting for age, race, gen-
der, months on dialysis at enrollment, and enrollment
hemoglobin level (Table 2). Not surprisingly, age was a
significant independent predictor of mortality in all 3
groups of patients (engendering a 3% to 5% increased
risk per age). As seen in the Kaplan-Meier survival
curves, hemoglobin as a categorical variable (12 vs.
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Fig. 1. Kaplan-Meier estimates of observed survival during follow-up
with regard to all cause mortality in hemodialysis (HD) patients strati-
fied by enrollment hemoglobin level. P  0.05
12 g/dL) was a significant independent mortality pre-
dictor for all patients [relative risk (RR)  2.13, P 
0.008) and for nondiabetics (RR  4.53, P  0.003), but
not for diabetic patients. Gender, race, and months of
dialysis at enrollment were not significant independent
mortality predictors in this model.
The results of the multivariate logistic regression anal-
ysis are shown in Table 3. Older age, presence of diabe-
tes, and enrollment dialysis vintage as well as lower hemo-
globin levels were associated with greater risk of death.
Age imparted a 5% increased risk per year, and each
month of dialysis at enrollment was associated with a
0.8% increase in mortality risk, while nondiabetics had
a 39% survival advantage. After adjusting for the other
variables in the model, each g/dL increase in hemoglobin
at enrollment was associated with a 17% decrease in the
mortality risk.
Survival by prealbumin. The cumulative observed sur-
vival of HD patients with enrollment prealbumin 30
mg/dL was significantly better (P  0.006) than that of
patients with prealbumin 30 mg/dL (data not shown).
Hemoglobin was weakly correlated with prealbumin in
HD patients (r  0.16, P  0.08).
Peritoneal dialysis
Demographics and patient characteristics and labora-
tory data. The mean age of PD patients was 54  16
years. Forty-one percent of the patients were diabetic,
and 53% were female (Table 1). The causes of ESRD
in PD patients were as follows: 35% diabetes; 30% hy-
pertension; 9% glomerulonephritis; 3% polycystic kid-
ney disease; 2% obstruction; 8% HIV; and 13% other/
unknown. The mean enrollment hemoglobin and serum
prealbumin levels were 9.62 1.77 g/dL and 35.5 11.1
mg/dL, respectively, while mean enrollment albumin was
3.43  0.66 g/dL, creatinine was 10.82  4.5 mg/dL, and
total cholesterol was 205  61 mg/dL. The mean and
Fig. 2. Kaplan-Meier estimates of observed survival during follow-up
with regard to all-cause mortality in nondiabetic hemodialysis (HD)
patients stratified by enrollment hemoglobin level. P  0.009
maximum follow-up times were 2.53 and 15.76 years,
respectively.
Survival analysis by hemoglobin. During this study
period, 178 of the 326 PD patients (54.6%) died. Perito-
neal dialysis patients were grouped by hemoglobin levels
12 g/dL and 12 g/dL. The cumulative observed sur-
vival of PD patients with enrollment hemoglobin 12
g/dL was significantly better (P  0.032) than that of
patients with hemoglobin 12 g/dL (Fig. 3). In nondia-
betics, cumulative observed survival of patients with he-
moglobin 12 g/dL was higher (P  0.058) than those
with hemoglobin 12 g/dL (Fig. 4). In diabetic PD pa-
tients, there was no significant difference in survival be-
tween the above 2 groups of patients (P  0.82). As
with HD patients, enrollment hemoglobin level was not
predictive of survival when stratified as greater than or
less than 11 g/dL (P  0.21) or as greater than or less
than 10 g/dL (P  0.54). Interestingly, observed survival
for PD patients with enrollment hemoglobin levels
12 g/dL was also significantly better than patients who
had enrollment hemoglobin of 10 to 11.99 g/dL (P 
0.04), a more common therapeutic range for anemia
management in chronic kidney disease (CKD) and dial-
ysis patients.
The independent predictors of patient survival in all
patients, nondiabetic and diabetic, were determined us-
ing a multivariate Cox proportional hazard analysis (Ta-
ble 4). Similar to HD, age was a significant predictor of
mortality in all 3 groups of patients (consistently engen-
dering a 3% increased risk per year of age). In addition,
hemoglobin as a categorical variable (12 vs.12 g/dL)
was a predictor of mortality for all patients (RR  1.85,
P  0.06) and nondiabetics (RR  2.02, P  0.07), but
not for diabetic patients. African race was a significant
survival advantage in diabetics (RR  1.62, P  0.04),
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Table 2. Independent predictors of mortality in HD patients in the multivariate Cox regression analysis
All patients Nondiabetic Diabetic
Variables RR P RR P RR P
Age years 1.04 0.0001 1.049 0.0001 1.028 0.002
Gender (female vs. male) 0.897 0.34 0.86 0.40 0.85 0.36
Race (others vs. African American) 1.07 0.61 0.86 0.41 1.37 0.082
Hemoglobin (12 vs. 12 g/dL) 2.13 0.008 4.53 0.003 0.74 0.39
Months on HD at enrollment 1.001 0.69 1.002 0.35 1.002 0.53
Abbreviations are: HD, hemodialysis; RR, relative risk.
Table 3. Multivariate logistic regression analysis of death risk in HD and PD patients
HD PD
Variables Odds ratio P Odds ratio P
Age years 1.05 0.0001 1.033 0.0001
Gender (female vs. male) 0.734 0.15 0.82 0.42
Race (others vs. African American) 1.07 0.76 0.80 0.37
Diabetes (no vs. yes) 0.61 0.02 0.76 0.26
Hemoglobin g/dL 0.83 0.002 0.85 0.02
Months on dialysis at enrollment 1.008 0.008 0.99 0.49
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis.
Fig. 3. Kaplan-Meier estimates of observed survival during follow-up
with regard to all-cause mortality in peritoneal dialysis (PD) patients
stratified by enrollment hemoglobin level. P  0.032
but gender and months of dialysis at enrollment were
not significant independent mortality predictors in this
model.
The results of the multivariate logistic regression anal-
ysis are shown in Table 3. In PD patients, older age and
lower hemoglobin levels were associated with greater
risk of death. Age imparted a 3% increased risk per
year, and after adjusting for the other variables in the
model, each g/dL increase in hemoglobin at enrollment
was associated with a 15% decrease in the mortality risk,
very similar to the finding in HD patients. As seen in
HD patients, hemoglobin was weakly correlated with
prealbumin in PD patients (r  0.17, P  0.09).
Survival by prealbumin. The cumulative observed sur-
vival of PD patients with enrollment prealbumin 30
Fig. 4. Kaplan-Meier estimates of observed survival during follow-up
with regard to all-cause mortality in nondiabetic peritoneal dialysis
(PD) patients stratified by enrollment hemoglobin level. P  0.058
mg/dL was significantly better (P  0.007) than that of
patients with prealbumin 30 mg/dL (data not shown).
Hemoglobin was weakly correlated with prealbumin in
PD patients (r  0.17, P  0.09).
DISCUSSION
The exact role of anemia in increasing mortality in
dialysis patients currently is not completely understood.
Anemia has profound physiologic effects in dialysis pa-
tients. Its presence activates the sympathetic nervous
system, which results in an increase in heart rate [14].
Maintenance of adequate tissue oxygen delivery in the
anemic state is achieved by both hemodynamic and non-
hemodynamic means. Nonhemodynamic adaptation in-
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Table 4. Independent predictors of mortality in PD patients in the multivariate Cox regression analysis
All patients Nondiabetic Diabetic
Variables RR P RR P RR P
Age years 1.032 0.0001 1.03 0.0001 1.03 0.002
Gender (female vs. male) 0.82 0.23 0.74 0.14 1.14 0.56
Race (others vs. African American) 1.32 0.08 1.06 0.80 1.62 0.04
Hemoglobin (12 vs. 12 g/dL) 1.85 0.06 2.02 0.07 1.15 0.81
Months on PD at enrollment 0.99 0.22 0.99 0.32 0.99 0.52
Abbreviations are: PD, peritoneal dialysis; RR, relative risk.
cludes increased erythropoietin production. Hemody-
namic changes include vasodilation, which leads to a
decreased systemic vascular resistance, which in turn
may affect stroke volume and tissue oxygenation [15].
Patients with CKD on dialysis also have a high preva-
lence of comorbid conditions such as hyperparathyroid-
ism, dyslipidemia, volume expansion, phosphate reten-
tion, which may contribute to myocardial fibrosis, and
calcium deposition into bone marrow with further resul-
tant aggravation of anemia [16–19].
The major finding of the present study is that dialysis
patients with enrollment hemoglobin levels 12 g/dL
had better long-term survival (over 15 years) compared
to those with lower hemoglobin levels. Using multivari-
ate Cox regression analysis, we observed that enrollment
hemoglobin as a categorical variable (12 g/dL vs.12 g/
dL) was an independent predictor of survival in HD
and PD patients. In addition, by multivariate logistic
regression analysis, a lower hemoglobin level signifi-
cantly predicted increased risk of death (Table 3). Some-
what surprisingly, we did not find similar survival advan-
tages when enrollment hemoglobin was stratified above
and below 11 g/dL or 10 g/dL in HD or PD patients. In
fact, in PD patients, hemoglobin12 g/dL was associated
with a significant survival advantage over patients with
hemoglobins between 10 g/dL and 11.999 g/dL, thereby
excluding outliers on the low end who might have other
serious intercurrent diseases which impact survival.
Inverse association of hemoglobin with mortality in
dialysis patients has been previously reported [20]. Ofsh-
stun et al [21], based upon a large population, has con-
comitantly reported a significant decreased risk of mor-
tality in HD patients with higher hemoglobins at
enrollment (12 g/dL). The relative risk of death contin-
ued to decrease as hemoglobin levels increased, with an
adjusted relative risk of death of 0.84 for the group with
12  hemoglobin  13 g/dL (P  0.007), compared to
the reference group of 11  hemoglobin  12 g/dL. In
contrast to our study, their report was of shorter duration
(6 months), and was limited to HD patients only. To
our knowledge, this is the first report concerning the
association of hemoglobin with survival in dialysis pa-
tients followed up to 15 years.
We examined the risk of mortality in diabetic and
nondiabetic patients separately. The higher relative risk
of mortality imparted by hemoglobin 12 g/dL in non-
diabetics compared to diabetics may be due to the ab-
sence of other comorbid conditions in nondiabetic pa-
tients. The reason for the difference in predictive power
of hemoglobin between HD and PD patients is unclear.
Our results support recent studies regarding the im-
portance of hemoglobin levels in predialysis patients. In
Reduction of Endpoints in NIDDM with the Angio-
tensin II Antagonist Losartan (RENAAL), individuals
who had hemoglobin levels 13.8 g/dL were found to
have the lowest rates of doubling of serum creatinine or
ESRD [22]. In addition, several small studies in patients
with CKD have suggested that progression of renal dis-
ease could be slowed with increased hemoglobin levels
[23–26].
In the present study, there was a trend in the positive
relationship between hemoglobin and prealbumin in HD
and PD patients. This implies that there may be a link
between malnutrition and anemia in dialysis patients.
Interestingly, it has been reported that correction of ane-
mia in HD patients improves the nutritional status in
HD patients [27]. We reported the importance of both
nutrition and dyslipidemia, but they need to be further
revisited [9, 28].
Raising the hemoglobin goals is a very controversial
issue. A recent pharmacoeconomic analysis concluded
that increasing hemoglobin levels to12 g/dL presented
an unfavorable cost-effectiveness ratio, and should not
be undertaken. We believe that many important issues
need to be evaluated when assessing the “cost-effective-
ness” of anemia management, including associated mor-
bidity, quality of life, and mortality, recently addressed
by Nissenson [29]. It is likely that erythropoietin costs
could be significantly curtailed by the judicious use of
intravenous iron [30, 31], by the use of calcimimetics [32]
to reduce bone resistance to erythropoietin, and possibly
by improving nutritional management, as suggested by
the correlation of prealbumin and hemoglobin in this
report. Future studies in patients with CKD, such as
Cardiovascular Risk Reduction by Early Anemia Treat-
ment with Epoetin beta trial (CREATE), may show that
higher hemoglobin levels (13 to 15 g/dL) may be even
better [33].
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CONCLUSION
Enrollment levels of hemoglobin influence long-term
survival in HD and PD patients. Patients with hemoglo-
bin above 12 g/dL, higher than the currently recom-
mended therapeutic target range, had better survival
than patients with lower hemoglobin. Our data suggests
that current therapeutic target ranges may need to be
re-evaluated in the light of mounting evidence that
higher levels may be advantageous to patients with CKD,
a high-risk population for cardiovascular events and pre-
mature death. In any case, increased vigilance in anemia
management is warranted, and may impact the long-
term survival of patients.
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